- Home
- PRTA vs GAIN Comparison
PRTA vs GAIN Comparison
Compare PRTA & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- GAIN
- Stock Information
- Founded
- PRTA 2012
- GAIN 2005
- Country
- PRTA Ireland
- GAIN United States
- Employees
- PRTA N/A
- GAIN N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- GAIN Finance: Consumer Services
- Sector
- PRTA Health Care
- GAIN Finance
- Exchange
- PRTA Nasdaq
- GAIN Nasdaq
- Market Cap
- PRTA 472.1M
- GAIN 551.1M
- IPO Year
- PRTA N/A
- GAIN 2005
- Fundamental
- Price
- PRTA $10.45
- GAIN $13.98
- Analyst Decision
- PRTA Buy
- GAIN Buy
- Analyst Count
- PRTA 9
- GAIN 2
- Target Price
- PRTA $17.71
- GAIN $14.00
- AVG Volume (30 Days)
- PRTA 567.7K
- GAIN 140.0K
- Earning Date
- PRTA 11-06-2025
- GAIN 11-04-2025
- Dividend Yield
- PRTA N/A
- GAIN 15.73%
- EPS Growth
- PRTA N/A
- GAIN 136.17
- EPS
- PRTA N/A
- GAIN 2.49
- Revenue
- PRTA $11,786,000.00
- GAIN $97,742,000.00
- Revenue This Year
- PRTA N/A
- GAIN $6.54
- Revenue Next Year
- PRTA $672.02
- GAIN $4.49
- P/E Ratio
- PRTA N/A
- GAIN $5.61
- Revenue Growth
- PRTA N/A
- GAIN 6.86
- 52 Week Low
- PRTA $4.32
- GAIN $11.42
- 52 Week High
- PRTA $18.65
- GAIN $15.34
- Technical
- Relative Strength Index (RSI)
- PRTA 56.63
- GAIN 54.56
- Support Level
- PRTA $10.02
- GAIN $13.56
- Resistance Level
- PRTA $11.17
- GAIN $13.94
- Average True Range (ATR)
- PRTA 0.56
- GAIN 0.24
- MACD
- PRTA -0.07
- GAIN 0.01
- Stochastic Oscillator
- PRTA 37.37
- GAIN 74.58
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.